280 related articles for article (PubMed ID: 30894372)
1. 4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer.
Wang Z; Feng X; Molinolo AA; Martin D; Vitale-Cross L; Nohata N; Ando M; Wahba A; Amornphimoltham P; Wu X; Gilardi M; Allevato M; Wu V; Steffen DJ; Tofilon P; Sonenberg N; Califano J; Chen Q; Lippman SM; Gutkind JS
Cancer Res; 2019 Apr; 79(7):1438-1450. PubMed ID: 30894372
[TBL] [Abstract][Full Text] [Related]
2. PDK1 Mediates
Sambandam V; Frederick MJ; Shen L; Tong P; Rao X; Peng S; Singh R; Mazumdar T; Huang C; Li Q; Pickering CR; Myers JN; Wang J; Johnson FM
Clin Cancer Res; 2019 Jun; 25(11):3329-3340. PubMed ID: 30770351
[TBL] [Abstract][Full Text] [Related]
3. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.
Nathan CO; Amirghahari N; Abreo F; Rong X; Caldito G; Jones ML; Zhou H; Smith M; Kimberly D; Glass J
Clin Cancer Res; 2004 Sep; 10(17):5820-7. PubMed ID: 15355912
[TBL] [Abstract][Full Text] [Related]
4. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
Herzog A; Bian Y; Vander Broek R; Hall B; Coupar J; Cheng H; Sowers AL; Cook JD; Mitchell JB; Chen Z; Kulkarni AB; Van Waes C
Clin Cancer Res; 2013 Jul; 19(14):3808-19. PubMed ID: 23640975
[TBL] [Abstract][Full Text] [Related]
5. The mTOR Targets 4E-BP1/2 Restrain Tumor Growth and Promote Hypoxia Tolerance in PTEN-driven Prostate Cancer.
Ding M; Van der Kwast TH; Vellanki RN; Foltz WD; McKee TD; Sonenberg N; Pandolfi PP; Koritzinsky M; Wouters BG
Mol Cancer Res; 2018 Apr; 16(4):682-695. PubMed ID: 29453322
[TBL] [Abstract][Full Text] [Related]
6. G-Protein-Coupled Receptor Kinase-Interacting Protein 1 (GIT1) Promotes Head and Neck Squamous Cell Carcinoma Metastases via Activating the PI3K/AKT/mTOR Signal Pathway.
Xu R; Xu R; Wang Y; Wang W; Jiang L; Gong S
Comput Math Methods Med; 2022; 2022():6881932. PubMed ID: 35116073
[TBL] [Abstract][Full Text] [Related]
7. Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that
Izumi H; Wang Z; Goto Y; Ando T; Wu X; Zhang X; Li H; Johnson DE; Grandis JR; Gutkind JS
Mol Cancer Ther; 2020 Jul; 19(7):1562-1571. PubMed ID: 32430488
[TBL] [Abstract][Full Text] [Related]
8. eIF4E and 4EBP1 are prognostic markers of head and neck squamous cell carcinoma recurrence after definitive surgery and adjuvant radiotherapy.
Huang CI; Wang CC; Tai TS; Hwang TZ; Yang CC; Hsu CM; Su YC
PLoS One; 2019; 14(11):e0225537. PubMed ID: 31756179
[TBL] [Abstract][Full Text] [Related]
9. TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function.
Schalm SS; Fingar DC; Sabatini DM; Blenis J
Curr Biol; 2003 May; 13(10):797-806. PubMed ID: 12747827
[TBL] [Abstract][Full Text] [Related]
10. Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladder.
Nishikawa M; Miyake H; Behnsawy HM; Fujisawa M
Urol Oncol; 2015 Apr; 33(4):166.e9-15. PubMed ID: 25618298
[TBL] [Abstract][Full Text] [Related]
11. Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling.
Kaur S; Lal L; Sassano A; Majchrzak-Kita B; Srikanth M; Baker DP; Petroulakis E; Hay N; Sonenberg N; Fish EN; Platanias LC
J Biol Chem; 2007 Jan; 282(3):1757-68. PubMed ID: 17114181
[TBL] [Abstract][Full Text] [Related]
12. Activation of the Akt/mammalian target of rapamycin pathway in combined hepatocellular carcinoma and cholangiocarcinoma: significant correlation between p-4E-BP1 expression in cholangiocarcinoma component and prognosis.
Okumura Y; Kohashi K; Tanaka Y; Kato M; Maehara Y; Ogawa Y; Oda Y
Virchows Arch; 2020 Jun; 476(6):881-890. PubMed ID: 31927624
[TBL] [Abstract][Full Text] [Related]
13. 4E-BP1, a multifactor regulated multifunctional protein.
Qin X; Jiang B; Zhang Y
Cell Cycle; 2016; 15(6):781-6. PubMed ID: 26901143
[TBL] [Abstract][Full Text] [Related]
14. Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma.
Chou MH; Chuang HC; Lin YT; Tsai MH; Kao YH; Lin IC; Huang TL; Fang FM; Chien CY
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802643
[TBL] [Abstract][Full Text] [Related]
15. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
[TBL] [Abstract][Full Text] [Related]
16. Mitosis-related phosphorylation of the eukaryotic translation suppressor 4E-BP1 and its interaction with eukaryotic translation initiation factor 4E (eIF4E).
Sun R; Cheng E; Velásquez C; Chang Y; Moore PS
J Biol Chem; 2019 Aug; 294(31):11840-11852. PubMed ID: 31201269
[TBL] [Abstract][Full Text] [Related]
17. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D
Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954
[TBL] [Abstract][Full Text] [Related]
18. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.
Ducker GS; Atreya CE; Simko JP; Hom YK; Matli MR; Benes CH; Hann B; Nakakura EK; Bergsland EK; Donner DB; Settleman J; Shokat KM; Warren RS
Oncogene; 2014 Mar; 33(12):1590-600. PubMed ID: 23542178
[TBL] [Abstract][Full Text] [Related]
19. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism.
Gingras AC; Gygi SP; Raught B; Polakiewicz RD; Abraham RT; Hoekstra MF; Aebersold R; Sonenberg N
Genes Dev; 1999 Jun; 13(11):1422-37. PubMed ID: 10364159
[TBL] [Abstract][Full Text] [Related]
20. Putative role of the mTOR/4E-BP1 signaling pathway in the carcinogenesis and progression of gastric cardiac adenocarcinoma.
Yang HY; Xue LY; Xing LX; Wang J; Wang JL; Yan X; Zhang XH
Mol Med Rep; 2013 Feb; 7(2):537-42. PubMed ID: 23229050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
